A prospective registry-based cohort study of the diagnosis and management of acute leukaemia in pregnancy: Study protocol

Matthew Northgraves, David Allsup, Judith Cohen, Chao Huang, John Turgoose, Sahra Ali, Matthew Northgraves, David Allsup, Judith Cohen, Chao Huang, John Turgoose, Sahra Ali

Abstract

Background: Acute leukaemias (AL) are aggressive but potentially curable blood cancers that can potentially affect women of childbearing age. When a pregnancy is complicated by a diagnosis of AL, clinicians face a complex dilemma: to balance risking the mother's survival through delayed AL treatment, against the potential harm to the foetus through exposure to anti-cancer drugs. Up until now, all guidance and advice regarding the management of AL in pregnancy, have been based on expert opinion and small case studies. There is a pressing need for more studies in the subject to address this evidence gap.

Methods and analysis: This study is a registry-based observational cohort study which aims to monitor and record the treatment outcomes of patients diagnosed with AL during pregnancy. Additionally, the study aims to assess pregnancy outcomes in patients who become pregnant following successful treatment. Prospective and historical cases from August 2009 onwards will be identified from AL treating haematology units within the UK. Details of diagnosis, AL treatment delivered, antenatal and postnatal outcomes for mother and neonate will be collected. This study will establish a new research database for Leukaemia in Pregnancy.

Trial registration: The study was registered on Clinicaltrials.gov (NCT04182074) on the 2nd December 2019.

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1. Procedure for processing cases with…
Fig 1. Procedure for processing cases with and without consent.

References

    1. Haematological Malignancy Research Network. Incidence statistics: Overall incidence—Total selected diagnoses 2021 [Available from: .
    1. Pavlidis NA. Coexistence of Pregnancy and Malignancy. The Oncologist. 2002;7(4):279–87.
    1. Reynoso EE, Shepherd FA, Messner HA, Farquharson HA, Garvey MB, Baker MA. Acute leukemia during pregnancy: the Toronto Leukemia Study Group experience with long-term follow-up of children exposed in utero to chemotherapeutic agents. J Clin Oncol. 1987;5(7):1098–106. doi: 10.1200/JCO.1987.5.7.1098
    1. Chelghoum Y, Vey N, Raffoux E, Huguet F, Pigneux A, Witz B, et al.. Acute leukemia during pregnancy: a report on 37 patients and a review of the literature. Cancer. 2005;104(1):110–7. doi: 10.1002/cncr.21137
    1. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al.. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453–74. doi: 10.1182/blood-2009-07-235358
    1. Carradice D, Austin N, Bayston K, Ganly PS. Successful treatment of acute promyelocytic leukaemia during pregnancy. Clin Lab Haematol. 2002;24(5):307–11. doi: 10.1046/j.1365-2257.2002.00459.x
    1. Agarwal K, Patel M, Agarwal V. A Complicated Case of Acute Promyelocytic Leukemia in the Second Trimester of Pregnancy Successfully Treated with All-trans-Retinoic Acid. Case Rep Hematol. 2015;2015:634252. doi: 10.1155/2015/634252
    1. Sanz MA, Montesinos P, Casale MF, Díaz-Mediavilla J, Jiménez S, Fernández I, et al.. Maternal and fetal outcomes in pregnant women with acute promyelocytic leukemia. Ann Hematol. 2015;94(8):1357–61. doi: 10.1007/s00277-015-2372-5
    1. Ali S, Jones GL, Culligan DJ, Marsden PJ, Russell N, Embleton ND, et al.. Guidelines for the diagnosis and management of acute myeloid leukaemia in pregnancy. Br J Haematol. 2015;170(4):487–95. doi: 10.1111/bjh.13554
    1. Shapira T, Pereg D, Lishner M. How I treat acute and chronic leukemia in pregnancy. Blood Rev. 2008;22(5):247–59. doi: 10.1016/j.blre.2008.03.006
    1. Brenner B, Avivi I, Lishner M. Haematological cancers in pregnancy. Lancet. 2012;379(9815):580–7. doi: 10.1016/S0140-6736(11)61348-2
    1. Stensheim H, Cvancarova M, Møller B, Fosså SD. Pregnancy after adolescent and adult cancer: a population-based matched cohort study. Int J Cancer. 2011;129(5):1225–36. doi: 10.1002/ijc.26045
    1. Das M, Shehata F, Son WY, Tulandi T, Holzer H. Ovarian reserve and response to IVF and in vitro maturation treatment following chemotherapy. Hum Reprod. 2012;27(8):2509–14. doi: 10.1093/humrep/des143
    1. Naessén S, Bergström I, Ljungman P, Landgren BM. Long-term follow-up of bone density, general and reproductive health in female survivors after treatment for haematological malignancies. Eur J Haematol. 2014;93(2):137–42. doi: 10.1111/ejh.12317
    1. Carter A, Robison LL, Francisco L, Smith D, Grant M, Baker KS, et al.. Prevalence of conception and pregnancy outcomes after hematopoietic cell transplantation: report from the Bone Marrow Transplant Survivor Study. Bone Marrow Transplant. 2006;37(11):1023–9. doi: 10.1038/sj.bmt.1705364
    1. Wang WS, Tzeng CH, Hsieh RK, Chiou TJ, Liu JH, Yen CC, et al.. Successful pregnancy following very high-dose total body irradiation (1575 cGy) and bone marrow transplantation in a woman with acute myeloid leukemia. Bone Marrow Transplant. 1998;21(4):415–7. doi: 10.1038/sj.bmt.1701106
    1. Henson KE, Elliss-Brookes L, Coupland VH, Payne E, Vernon S, Rous B, et al.. Data Resource Profile: National Cancer Registration Dataset in England. International Journal of Epidemiology. 2019;49(1):16–h.
    1. Bright CJ, Lawton S, Benson S, Bomb M, Dodwell D, Henson KE, et al.. Data Resource Profile: The Systemic Anti-Cancer Therapy (SACT) dataset. International Journal of Epidemiology. 2019;49(1):15–l.
    1. Juliusson G, Lazarevic V, Hörstedt AS, Hagberg O, Höglund M. Acute myeloid leukemia in the real world: why population-based registries are needed. Blood. 2012;119(17):3890–9. doi: 10.1182/blood-2011-12-379008
    1. Maggen C, Wolters V, Cardonick E, Fumagalli M, Halaska MJ, Lok CAR, et al.. Pregnancy and Cancer: the INCIP Project. Curr Oncol Rep. 2020;22(2):17. doi: 10.1007/s11912-020-0862-7
    1. Health Research Authority. Confidentiality Advisory Group 2021 [Available from: .
    1. Public Health Scotland. Public Benefit and Privacy Panel for Health and Social Care-HSC-PBPP 2021 [Available from: .
    1. NHS Digital. National data opt-out 2021 [Available from: .
    1. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bmj. 2007;335(7624):806–8. doi: 10.1136/
    1. Health Research Authority. Research tissue banks and research databases 2021 [updated 7th July 2021. Available from: .
    1. Ostgård LS, Nørgaard JM, Severinsen MT, Sengeløv H, Friis L, Jensen MK, et al.. Data quality in the Danish National Acute Leukemia Registry: a hematological data resource. Clin Epidemiol. 2013;5:335–44. doi: 10.2147/CLEP.S48411

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi